Protagenic Therapeutics (PTIX) Stock Price, Quote, News & History

Protagenic Therapeutics Inc (PTIX) Stock Price, Quote, News & History

PTIXOTCQB

Trade with Public

At close: Jan 16, 4:00 PM EST

Key Statistics

Open

Volume / Avg.

23.59K / 60.56K

Day Range

- - -

52 Wk Range

0.25 - 14.28

Market Cap

$1.34M

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

1.3

Recent Protagenic Therapeutics Inc News

PRO
Protagenic Therapeutics Reports Topline Phase 1 Safety Data For PT00114, Was Well Tolerated Across All Dose Ranges Studied; Paves Way For Phase 2 In Stress-Related Neuropsychiatric Conditions

Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditionsNEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic Therapeutics Inc.

Benzinga Newsdesk

PRO
Protagenic Therapeutics Completes Enrollment, Dosing In Its Multiple Ascending Dose Phase 1 Trial Evaluating PT00114

Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and neurodegenerative disorders, today announced the successful completion of

Benzinga Newsdesk

PRO
Protagenic Therapeutics shares are trading lower after the company filed a complaint to rescind its share exchange agreement by which it acquired Phytanix Bio.

Benzinga Newsdesk

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-3.63M

Investing Cash Flow (TTM)

1.60M

Financing Cash Flow (TTM)

2.07M

Free Cash Flow (TTM)

-3.63M

Capital Expenditure (TTM)

Net Change in Cash (TTM)

40.72K

Valuation Metrics

Enterprise Value

$2.32M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

PB Ratio (TTM)

Earnings Yield % (TTM)

-2420.70%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

-$2.44

Company Debt

Total Debt

$4.00M

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

Total Cash

$2.72M

Debt to Equity

Issuance of Debt (TTM)

Repayment of Debt (TTM)

Key Statistics

Open

Volume / Avg.

23.59K / 60.56K

Day Range

- - -

52 Wk Range

0.25 - 14.28

Market Cap

$1.34M

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

1.3

About

Sector

Health Care

Industry

Biotechnology

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerati...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Protagenic Therapeutics (PTIX) stock?

You can purchase shares of Protagenic Therapeutics (OTCQB:PTIX) through any online brokerage.

View our list of the best stock brokerages

Who are Protagenic Therapeutics (PTIX) competitors?

There are no as such competitors for Protagenic Therapeutics.

What is the forecast, or price target, for Protagenic Therapeutics (PTIX) stock?

There is no analysis for Protagenic Therapeutics to provide a consensus price target.

What is the current price for Protagenic Therapeutics (PTIX)?

The stock price for Protagenic Therapeutics (OTCQB: PTIX) is $0.695 last updated March 18, 2026 at 1:26 PM EDT.

Does Protagenic Therapeutics (PTIX) pay a dividend?

There are no upcoming dividends for Protagenic Therapeutics.

When is Protagenic Therapeutics (OTCQB:PTIX) reporting earnings?

Protagenic Therapeutics does not have any upcoming earnings scheduled.

Is Protagenic Therapeutics (PTIX) going to split?

There is no upcoming split for Protagenic Therapeutics.

What sector and industry does Protagenic Therapeutics (PTIX) operate in?

Protagenic Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the OTCQB.

Key Statistics

Open

Volume / Avg.

23.59K / 60.56K

Day Range

- - -

52 Wk Range

0.25 - 14.28

Market Cap

$1.34M

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

1.3

Recent Protagenic Therapeutics Inc News

PRO
Protagenic Therapeutics Reports Topline Phase 1 Safety Data For PT00114, Was Well Tolerated Across All Dose Ranges Studied; Paves Way For Phase 2 In Stress-Related Neuropsychiatric Conditions

Benzinga Newsdesk

PRO
Protagenic Therapeutics Completes Enrollment, Dosing In Its Multiple Ascending Dose Phase 1 Trial Evaluating PT00114

Benzinga Newsdesk

PRO
Protagenic Therapeutics shares are trading lower after the company filed a complaint to rescind its share exchange agreement by which it acquired Phytanix Bio.

Benzinga Newsdesk